Human Pathology
Volume 41, Issue 1 , Pages 26-32, January 2010

Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins

  • Agnieszka K. Witkiewicz, MD

      Affiliations

    • Department of Pathology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    • Corresponding Author InformationCorresponding author.
  • ,
  • Thomas McConnell, MD

      Affiliations

    • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
  • ,
  • Magdalena Potoczek

      Affiliations

    • Department of Pathology, Thomas Jefferson University, Philadelphia, PA 19107, USA
  • ,
  • Robert V.B. Emmons, MD

      Affiliations

    • BMT Division, Department of Medicine, Temple University, Philadelphia, PA 19111, USA
  • ,
  • Robert J. Kurman, MD

      Affiliations

    • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

Received 17 April 2009; received in revised form 12 June 2009; accepted 19 June 2009. published online 07 September 2009.

Summary 

Progestins are used to treat complex atypical hyperplasia and well-differentiated endometrial carcinoma in women who desire fertility preservation and those who are poor surgical candidates. Although sensitivity to progestins is thought to be associated with the presence of estrogen and progesterone receptors, it is known that receptor-negative tumors can also respond to the agent, suggesting that there is another direct antitumor action of progestin. Because tumor immune response is an additional predictor of survival in well-differentiated endometrial carcinoma, it is surprising that the role of progestins in tumor immunity has not been investigated. Regulatory T cells modulate the immune response, whereas cytotoxic T cells directly target tumor cells. In this study, we investigated the effect of progestins on regulatory T cells and cytotoxic T cells. The pre- and posttreatment endometrial samples of 15 progestin-treated patients with complex atypical hyperplasia or well-differentiated endometrial carcinoma were evaluated for therapeutic response and the presence of cytotoxic T cells and regulatory T cells. Immunohistochemical analysis was performed for FOXP3 to identify regulatory T cells and for granzyme B to identify activated cytotoxic T cells. To further characterize the cytotoxic T cell's subpopulations, we performed CD8 (cytotoxic T-cell marker) and CD56 (natural killer cells marker). Ten of 15 patients had normal morphology on follow-up endometrial samplings, and 4 patients had persistence or progression of the disease. Regulatory T-cell counts pretreatment were significantly higher in complex atypical hyperplasia and well-differentiated endometrial carcinoma than in posttreatment normal endometrium. Residual complex atypical hyperplasia and well-differentiated endometrial carcinoma present in posttreatment samples maintained high regulatory T cells and low number of cytotoxic T cells. Progestin treatment was associated with striking increase in cytotoxic T cells in areas with decidual reaction. Before treatment, most of the granzyme B+ cytotoxic T cells in complex atypical hyperplasia and well-differentiated endometrial carcinoma were CD8+ T cells, whereas after treatment, up to 80% of cytotoxic T cells were natural killer cells. These results suggest that progestin treatment affects subpopulations of lymphocytes in the endometrium and may induce immune suppression of complex atypical hyperplasia and well-differentiated endometrial carcinoma.

Keywords: Endometrial carcinoma, Progestin

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0046-8177(09)00231-7

doi:10.1016/j.humpath.2009.06.012

Human Pathology
Volume 41, Issue 1 , Pages 26-32, January 2010